|
Title
|
Status
|
|
|
Recruiting
in 1 of 1 locations
|
|
Breast Cancer is the most commonly diagnosed cancer in women in North America. Despite effective therapies, many women develop metastatic disease (ie disease that has spread outside of the breast to other parts of the body). For these women, the goal of care is to improve quality of life and, where possible, prolong quantity of life. The most common site of metastatic disease is spread to the bone. Bone metastases can significantly affect patients quality of life by causing pain, fractures, spinal cord compression, and life-threatening biochemical abnormalities (high calcium in the blood). Bisphosphonate drugs are medications that have been proven to decrease the frequency of these events. At present, however, the best way to deliver these drugs is not known. We aim to develop a risk score for women with bone metastases, so that we can stratify women into low, medium, and high risk categories. This will allow us to tailor treatment for bone metastases based on risk category.
|
|
|
Recruiting
in 0 of 3 locations
|
|
The study will investigate the comparative efficacy and safety of two oral inhibitors of Kit and PDGFR: nilotinib 400 mg bid, a novel agent, and imatinib 400 mg bid, an approved agent with an established efficacy.
|
|
|
Recruiting
in 8 of 8 locations
|
|
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and
either kill them or deliver tumor-killing substances to them without harming normal cells.
Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill cancer
cells. It is not yet known if chemotherapy is more effective with or without monoclonal
antibody therapy, interleukin-2, and sargramostim following stem cell transplantation in
treating neuroblastoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with or
without monoclonal antibody, interleukin-2, and sargramostim following stem cell
transplantation in treating patients who have neuroblastoma.
|
|
|
Recruiting
in 1 of 1 locations
|
|
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
|
|
|
Recruiting
in 2 of 2 locations
|
|
This is a double-blind, randomized, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of metastatic (stage IV) or advanced stage IIIB with malignant pleural effusion NSCLC. Approximately 3000 subjects with metastatic (stage IV) or advanced stage IIIB with malignant pleural effusion NSCLC receiving or about to receive first line chemotherapy will be enrolled into the study. Subjects will be randomized in a 2:1 allocation (Group A: darbepoetin alfa 500 µg Q3W, Group B: placebo Q3W)
|
|
|
Recruiting
in 4 of 4 locations
|
Stereotactic radiation therapy can send x-rays directly to the tumour and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumour cells. It is not yet known whether stereotactic radiation therapy is more effective with or without whole-brain radiation therapy in treating patients with brain metastases.
This randomized phase III trial is studying stereotactic radiation therapy and whole-brain radiation therapy to see how well they work compared with stereotactic radiation therapy alone in treating patients with brain metastases.
|
|
|
Recruiting
in 1 of 1 locations
|
|
Hepatocellular carcinoma (HCC) is one of the most common causes of global cancer death, with an increasing incidence in North America. Most patients are not suitable for surgery. Ablative therapies are an alternative treatment for some, but most patients have tumours too large for this. Stereotactic body radiation therapy (SBRT) refers to radiation therapy delivered precisely with a high dose volume conforming closely to the tumour, usually in less than 10 treatment fractions.
|
|
|
Recruiting
in 22 of 23 locations
|
|
To determine if Accelerated Partial Breast Irradiation, using 3D CRT, is as effective as
Whole Breast Irradiation following breast conserving surgery in women with an new
histological diagnosis of ductal carcinoma in situ only or invasive breast cancer without
evidence of metastatic disease. Effectiveness will be determined by the rate of ipsilateral
breast tumour recurrence.
General objective is to improve the convenience and quality of life of female patients who
receive breast irradiation.
|
|
|
Recruiting
in 1 of 1 locations
|
|
A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumour activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with advanced or metastatic solid tumours. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with paclitaxel and carboplatin for Phase 2 studies.
|
|
|
Recruiting
in 1 of 1 locations
|
|
The project outline which follows is a pilot investigation aimed at improving MRI parameters
in DCE-MRI to optimize the detection of treatment responses in LABC.
The primary objective is to define the activity of neoadjuvant chemotherapy in patients with
biopsy proven operable breast cancer. Secondary objectives include evaluating a new MRI
pulse sequence to optimize DCE-MRI of LABC responses.
|
